Alpha-1 Antitrypsin Deficiency Infusion Therapy in Portland, Oregon
Alpha-1 Antitrypsin Deficiency Infusion Therapy in Portland, Oregon
For patients living with alpha-1 antitrypsin deficiency (AATD), ongoing lung protection and consistent treatment can make a meaningful difference. Alpha-1 antitrypsin deficiency is an inherited condition in which the body does not make enough alpha-1 antitrypsin, a protein that helps protect the lungs from damage. Over time, some patients develop emphysema or other COPD-like lung disease, including people who have never smoked.
For eligible patients, augmentation therapy may be prescribed to increase alpha-1 proteinase inhibitor levels. FDA-approved therapies include Prolastin-C®, Glassia®, and Aralast NP®, which are given by intravenous infusion. These products are approved for augmentation or chronic replacement therapy in adults with severe alpha-1 proteinase inhibitor deficiency and clinically evident emphysema or lung disease, depending on product labeling.
At Vital Care of Portland, we support patients acrossOregon with infusion care that is local, flexible, and coordinated with the prescribing specialist. Depending on the patient’s treatment plan and insurance requirements, therapy may be delivered in the home or in an infusion suite.
What is alpha-1 antitrypsin deficiency?
Alpha-1 antitrypsin deficiency, sometimes called AAT deficiency or Alpha-1, is a genetic disorder that can affect the lungs and liver. In adults, one of the most important pulmonary concerns is the increased risk of emphysema caused by low levels of alpha-1 antitrypsin in the body. The Alpha-1 Foundation notes that augmentation therapy is used for some people with Alpha-1 to raise the levels of AAT protein in the lungs.
Because AATD is a chronic condition, treatment often involves more than just the medication itself. Patients and families frequently need ongoing coordination around scheduling, nursing support, insurance benefits, and communication with the prescribing pulmonologist or specialist.
How Prolastin, Glassia, and Aralast infusions work
Prolastin-C, Glassia, and Aralast NP are alpha1-proteinase inhibitor therapies derived from human plasma and administered intravenously. Product labeling describes these therapies as ongoing augmentation, maintenance, or replacement treatment for patients with severe hereditary deficiency and clinically evident emphysema or lung disease.
These infusions are commonly prescribed on a weekly schedule, and FDA labeling for Prolastin-C and Aralast NP includes a dose of 60 mg/kg administered intravenously once weekly.
While the exact infusion process can vary by product and prescriber instructions, treatment generally involves:
IV access placement by a trained clinician
medication preparation and administration per product requirements
monitoring during infusion
observation for infusion-related side effects such as headache, chills, or other reactions noted in product labeling
Who may benefit from augmentation therapy?
Patients may be candidates for alpha-1 infusion therapy when they have:
confirmed alpha-1 antitrypsin deficiency
evidence of clinically significant lung involvement
a treatment plan from a pulmonologist or other qualified specialist
Not every patient with AATD will be treated the same way, and augmentation therapy is not a cure. The Alpha-1 Foundation describes augmentation therapy as a treatment that can raise protective protein levels, while noting that broader disease management may still include other pulmonary therapies and specialist care.
Home infusion or infusion suite: what are the options?
For many Oregon patients, one of the biggest questions is not just which therapy is prescribed, but where treatment can happen.
Depending on clinical appropriateness, payer requirements, and patient preference, alpha-1 infusion therapy may be delivered:
at home, for patients who value convenience and routine weekly care
in an infusion suite, for patients who prefer a supervised clinical setting
For a long-term therapy like augmentation treatment, consistency matters. Patients often want an infusion provider that can offer dependable scheduling, clear communication, and a smoother care experience over time.
What to look for in an infusion provider in Oregon
If you are comparing infusion providers for Prolastin, Glassia, or Aralast in Oregon, it helps to look for a team that can support both the clinical and logistical side of care.
Important considerations include:
experienced infusion nurses
reliable recurring scheduling
coordination with the prescribing pulmonologist or specialist
support with insurance and benefit review
local availability for patients in Portland and surrounding Oregon communities
At Vital Care of Portland, we focus on making specialty infusion care feel more personal and more manageable. Our team works to coordinate therapy, communicate with the referring office, and help patients receive treatment in the setting that best fits their needs.
Pulmonary and immunology infusion support in Oregon
Some patients seen by pulmonology, allergy, or immunology specialists may also require other infused therapies as part of their broader care plan. While this page is focused on alpha-1 antitrypsin deficiency infusion therapy, Vital Care of Portland also supports other specialty infusion needs across Oregon based on the patient’s diagnosis, prescription, and insurance pathway.
Why patients choose Vital Care of Portland
Choosing an infusion provider is about more than access to medication. It is also about the experience of care week after week.
Patients and referring providers often value:
local Oregon-based coordination
flexible scheduling options
home and infusion suite availability
communication with specialists
a team that understands long-term specialty infusion therapy
If you are looking for alpha-1 antitrypsin deficiency infusion therapy in Portland, Oregon, Vital Care of Portland is here to help support the next step.
Get started with alpha-1 infusion therapy in Portland, Oregon
If you or a loved one has been diagnosed with alpha-1 antitrypsin deficiency and your specialist has prescribed augmentation therapy, our team can help coordinate care.
Contact Vital Care of Portland to learn more about:
Prolastin infusion therapy
Glassia infusion
Aralast infusion
home infusion options in Oregon
infusion suite scheduling near Portland
FAQ section
What is alpha-1 antitrypsin deficiency?
Alpha-1 antitrypsin deficiency is an inherited condition in which the body does not produce enough alpha-1 antitrypsin, a protein that helps protect the lungs. In some adults, this can lead to emphysema or other lung disease.
What is augmentation therapy for alpha-1 antitrypsin deficiency?
Augmentation therapy is an intravenous treatment that raises alpha-1 antitrypsin levels using purified alpha1-proteinase inhibitor from human plasma. It is used for certain patients with severe deficiency and lung disease.
What infusion therapies are used for Alpha-1?
Common FDA-approved alpha1-proteinase inhibitor therapies include Prolastin-C, Glassia, and Aralast NP.
How often are Prolastin, Glassia, or Aralast infusions given?
Many patients receive augmentation therapy on a weekly schedule. Product labeling for Prolastin-C and Aralast NP includes dosing at 60 mg/kg once weekly.
Can alpha-1 infusion therapy be done at home?
Depending on the patient’s treatment plan, insurance coverage, and clinical circumstances, infusion therapy may be given at home or in an infusion suite. The appropriate setting is determined by the care team and payer requirements.
Where can I get alpha-1 antitrypsin deficiency infusion therapy in Portland, Oregon?
Patients in the Portland area may be able to receive therapy through a local infusion provider that coordinates with their pulmonologist or specialist and offers home or infusion suite options.
What should I look for in an infusion provider?
Look for nursing experience, scheduling reliability, communication with your specialist, and support with benefits and care coordination.
